Brief: Xbiotech Executes Manufacturing Agreement With Janssen Research & Development
02/02/2022 15:10
Feb 2 (Reuters) - Johnson & Johnson JNJ.N :
* XBIOTECH INC - EXECUTED MANUFACTURING AGREEMENT WITH
JANSSEN
RESEARCH & DEVELOPMENT, LLC TO MANUFACTURE CLINICAL PRODUCT,
INCLUDING BERMEKIMAB
* XBIOTECH INC - NEW AGREEMENT WILL EXTEND XBIOTECH'S
MANUFACTURING SUPPORT UNTIL DECEMBER, 2023
Source text for Eikon: ID:nGNE79KN3B
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke